Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?
about
Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive CancersClass III β-tubulin counteracts the ability of paclitaxel to inhibit cell migrationNew insights into mechanisms of resistance to microtubule inhibitorsEribulin in Cancer TreatmentMicrotubule-binding agents: a dynamic field of cancer therapeutics.High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancerRole of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate CancerClass III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancerMicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agentsβIII-Tubulin: biomarker of taxane resistance or drug target?Specific β-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cellsAnticancer agent shikonin is an incompetent inducer of cancer drug resistanceInfluence of Matrices on 3D-Cultured Prostate Cancer Cells' Drug Response and Expression of Drug-Action Associated ProteinsPrognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodellingClass III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancerDesign, synthesis, and biological evaluations of 2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoline analogs of combretastatin-A4.Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents.Tubulin proteomics: towards breaking the code.Tubulin Beta-3 Chain as a New Candidate Protein Biomarker of Human Skin Aging: A Preliminary Study.Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung CancerQuantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment.A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancerIdentification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells.Distinct functional roles of β-tubulin isotypes in microtubule arrays of Tetrahymena thermophila, a model single-celled organismSynthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistanceOverexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy.In vitro and in vivo therapeutic approach for a small cell carcinoma of the ovary hypercalcaemic type using a SCCOHT-1 cellular model.ELR510444, a novel microtubule disruptor with multiple mechanisms of actionHallmarks of molecular action of microtubule stabilizing agents: effects of epothilone B, ixabepilone, peloruside A, and laulimalide on microtubule conformation.The herb medicine formula "chong lou fu fang" increases the cytotoxicity of chemotherapeutic agents and down-regulates the expression of chemotherapeutic agent resistance-related genes in human gastric cancer cells in vitro.The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis.Drugs that target dynamic microtubules: a new molecular perspectiveβIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancerβIII-Tubulin Regulates Breast Cancer Metastases to the Brain.Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cellsCross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.Bilateral breast cancer following augmentation mammaplasty with polyacrylamide hydrogel injection: A case reportNek6 and Hif-1α cooperate with the cytoskeletal gateway of drug resistance to drive outcome in serous ovarian cancer.6-Methoxy Podophyllotoxin Induces Apoptosis via Inhibition of TUBB3 and TOPIIA Gene Expressions in 5637 and K562 Cancer Cell Lines.
P2860
Q21296833-1565386C-F950-4814-ADFD-CB8E8617B745Q24617268-A25D7263-BFCB-4854-9791-08638808F3B4Q24633853-B74B02FA-5539-49A0-8EE7-A49731D17F2CQ26799328-473FE23F-56DC-4935-A66A-6FC057CD5912Q27690249-0BCCFCB0-FEA5-4013-B665-2FB0ADC69D22Q27851983-E8DC681B-2496-4272-91C1-23BD44F4B5FAQ28075965-96364B98-FC5D-4DCC-A68C-5A0A2FAC23A2Q28236320-7143D6A7-4CD7-428D-B509-77F6CF2EA1C8Q28244659-2CDE3143-FF93-4E4D-8966-7AD068A15C66Q28284878-ACA282A7-9375-4DF9-8AB0-AD6D8BFB6E16Q28478885-73533D0A-0031-45FC-A668-B68CC641B8BBQ28484828-87C6C417-0166-46E9-9177-CAF283D4DC03Q28552225-95BC5CB5-8ED3-46A5-AFF0-9C31F2C2786BQ32187309-2D3F23C2-084D-427D-A0F4-591A7B49B813Q33559947-B0210E9B-9A7C-4209-92EF-0F2154C9F16EQ33589802-5584BACB-660B-49FC-A57F-5869FEC2BB17Q33606508-CA9A0BFE-9CB0-4CA3-BB80-FE7204CE595CQ33630855-4C2D63F0-1588-46DA-97A5-2FF5FB8A8E1CQ33687990-59CE766F-5EF1-4747-A21A-56052DC57161Q33775713-6ABADA10-3996-48C5-8128-A858FB3A4C9EQ33844457-2617757E-0B8F-472A-93FC-23BF2A4040BBQ33914197-5F67FC6F-2367-46BC-A39C-2570AA50A603Q34243429-C4A70A64-EA02-4B9A-A472-4D5D65B0BA80Q34313834-FA37C06D-8727-4F57-8514-87D0FB807D69Q34321628-C53832F8-03E5-4BEF-89A9-5E1621665331Q34336551-B8F2648E-FB4B-4AD1-9ABE-BF5CB6252E36Q34428153-F852F493-3E40-48CA-BD58-4065AC5B6BFBQ34598957-4BA2091C-8DAB-4849-A643-B6CC22B4FE25Q34702388-19742CA9-CD72-4928-9FF1-771693049FC7Q34719865-233A95D3-0996-4385-A82B-A0CF561FA8EDQ35109129-FF33DCD4-8F7C-49FA-93A0-17DB52AE0386Q35140489-CE3D4DA0-5BE9-4F4C-B02F-E4D5ABFFB567Q35163252-1AE30DF2-799D-4CC6-85CF-5C19B9573F4DQ35273536-6395FFFE-8C9F-44E7-8453-A9ADC2AB65BBQ35587344-52036C67-8DD5-49E3-8B9D-8542209D3D36Q35723911-BAAE6FBD-07A4-4E14-8318-27ED80AFDEBCQ35747285-C96CDFB8-CF5E-4AFD-B2B2-DEE3A69BF549Q35758146-F53BB3FA-26C2-4265-992D-543F18F49B77Q35929796-1999278F-9DF5-411A-BE61-B545E5878C03Q36148796-B60B6AA8-3B7E-4EF3-88C4-09551212197D
P2860
Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Is class III beta-tubulin a pr ...... eiving tubulin-binding agents?
@en
Is class III beta-tubulin a pr ...... eiving tubulin-binding agents?
@nl
type
label
Is class III beta-tubulin a pr ...... eiving tubulin-binding agents?
@en
Is class III beta-tubulin a pr ...... eiving tubulin-binding agents?
@nl
prefLabel
Is class III beta-tubulin a pr ...... eiving tubulin-binding agents?
@en
Is class III beta-tubulin a pr ...... eiving tubulin-binding agents?
@nl
P1433
P1476
Is class III beta-tubulin a pr ...... eiving tubulin-binding agents?
@en
P2093
Pascal Sève
P304
P356
10.1016/S1470-2045(08)70029-9
P50
P577
2008-02-01T00:00:00Z